Market Overview

UPDATE: JP Morgan Downgrades Affymetrix to Underweight

Share:
Related AFFX
Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher
Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump On Upbeat Earnings
Related AFFX
Stocks Hitting 52-Week Highs
Is Illumina Worth Adding To Your Portfolio?

JP Morgan lowered its rating on Affymetrix (NASDAQ: AFFX) from Neutral to Underweight on macro risk.

JP Morgan said, "We are lowering our rating on AFFX from Neutral to Underweight on the poor outlook for arrays in academic/research, and limited flexibility for capital deployment following the eBiosciences acquisition. ... With increasing competition in arrays from Illumina and Agilent (Roche even felt the need to exit arrays recently), as well as sequencing and other platforms (desktop sequencers, nanofluidics platforms, etc.), we see little to stabilize the array business, particularly against the backdrop of a challenging U.S. and EU funding environment."

Affymetrix closed at $4.41 on Tuesday.

Latest Ratings for AFFX

DateFirmActionFromTo
Jan 2015BairdDowngradesOutperformNeutral
Oct 2014BTIG ResearchInitiates Coverage onNeutral
May 2014Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for AFFX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (AFFX)

Around the Web, We're Loving...

Get Benzinga's Newsletters